Mykofenolát Mofetil Sandoz (Mycophenolate Mofetil)

Mycophenolate Mofetil, the active ingredient in Mykofenolát Mofetil Sandoz, is an immunosuppressant presented as an oral formulation for oral use. It is employed to prevent organ transplant rejection and to treat lupus nephritis by moderating the immune response in transplant recipients and patients with severe renal involvement of systemic lupus erythematosus.

GNH USA supplies Mykofenolát Mofetil Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Mykofenolát Mofetil Sandoz is an immunosuppressive antimetabolite used in conditions where immune modulation is required.

- Organ transplant rejection: helps prevent graft loss by inhibiting lymphocyte proliferation. - Kidney transplant: maintains renal allograft function through sustained immune suppression. - Lupus nephritis: reduces renal inflammation and proteinuria in systemic lupus erythematosus.

Adverse reactions may range from mild to severe and should be monitored throughout therapy.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: frequent loose stools. - Headache: transient cranial discomfort. - Abdominal pain: cramping or discomfort. - Infections: increased susceptibility to bacterial and viral infections.

Serious or Rare Side Effects: - Leukopenia: significant reduction in white blood cells. - Severe infections: opportunistic or life‑threatening infections. - Hepatotoxicity: elevated liver enzymes or liver injury. - Malignancy: increased risk of certain cancers with long‑term use. - Progressive multifocal leukoencephalopathy: rare demyelinating disease.

Careful monitoring and patient education are essential when using Mykofenolát Mofetil Sandoz. - Blood counts: monitor complete blood count regularly to detect leukopenia. - Renal function: assess serum creatinine and glomerular filtration rate. - Live vaccines: avoid administration while on therapy. - Pregnancy: contraindicated in pregnancy; use effective contraception. - Breastfeeding: not recommended due to drug excretion in milk. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Mycophenolate Mofetil may interact with several medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Azathioprine: additive bone‑marrow suppression. - Cyclosporine: increased risk of nephrotoxicity and infections. - Rifampin: reduces mycophenolate plasma concentrations.

Moderate Interactions (Monitor Closely): - Antacids (aluminum or magnesium): may decrease absorption. - Warfarin: monitor INR for potential anticoagulant effect changes. - Live vaccines: heightened infection risk; consider timing.